🇺🇸 FDA
Patent

US 10500290

Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer

granted A61KA61K38/00A61K45/06

Quick answer

US patent 10500290 (Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K38/00, A61K45/06, A61K49/0032, A61K49/0043